{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:26:39Z","timestamp":1788560799481,"version":"build-2803163510"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s10072-019-03778-7","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T08:27:35Z","timestamp":1551947255000},"page":"661-669","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5204-7826","authenticated-orcid":false,"given":"Giuseppe","family":"Vita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Stancanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"key":"3778_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","volume":"50","author":"M Koenig","year":"1987","unstructured":"Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50:509\u2013517","journal-title":"Cell"},{"key":"3778_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919\u2013928","journal-title":"Cell"},{"key":"3778_CR3","first-page":"139","volume":"3","author":"JM Ervasti","year":"1993","unstructured":"Ervasti JM, Campbell KP (1993) Dystrophin-associated glycoproteins: their possible roles in the pathogenesis of Duchenne muscular dystrophy. Mol Cell Biol Hum Dis Ser 3:139\u2013166","journal-title":"Mol Cell Biol Hum Dis Ser"},{"key":"3778_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.molmed.2004.08.007","volume":"10","author":"G Cossu","year":"2004","unstructured":"Cossu G, Sampaolesi M (2004) New therapies for muscular dystrophy: cautious optimism. Trends Mol Med 10:516\u2013520","journal-title":"Trends Mol Med"},{"key":"3778_CR5","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jama.1991.03460070075046","volume":"265","author":"CH Asbury","year":"1991","unstructured":"Asbury CH (1991) The orphan drug act. The first 7 years. JAMA 265:893\u2013897","journal-title":"JAMA"},{"key":"3778_CR6","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00228-012-1423-2","volume":"69","author":"R Joppi","year":"2013","unstructured":"Joppi R, Bertel\u00e8 V, Garattini S (2013) Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol 69:1009\u20131024","journal-title":"Eur J Clin Pharmacol"},{"key":"3778_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"V Plant\u00e9-Bordeneuve","year":"2011","unstructured":"Plant\u00e9-Bordeneuve V, Said G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10:1086\u20131097","journal-title":"Lancet Neurol"},{"key":"3778_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jns.2009.05.001","volume":"284","author":"G Said","year":"2009","unstructured":"Said G, Plant\u00e9-Bordeneuve V (2009) Familial amyloid polyneuropathy: a clinico-pathologic study. J Neurol Sci 284:149\u2013154","journal-title":"J Neurol Sci"},{"issue":"Suppl 1","key":"3778_CR9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/13506129.2003.12088561","volume":"10","author":"G Said","year":"2003","unstructured":"Said G (2003) Familial amyloid polyneuropathy: mechanisms leading to nerve degeneration. Amyloid 10(Suppl 1):7\u201312","journal-title":"Amyloid"},{"key":"3778_CR10","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/archneur.61.7.1097","volume":"61","author":"A Mazzeo","year":"2004","unstructured":"Mazzeo A, Aguennouz M, Messina C, Vita G (2004) Immunolocalization and activation of transcription factor nuclear factor kappa B in dysimmune neuropathies and familial amyloidotic polyneuropathy. Arch Neurol 61:1097\u20131102","journal-title":"Arch Neurol"},{"key":"3778_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3109\/13506129.2014.927759","volume":"21","author":"NP Gon\u00e7alves","year":"2014","unstructured":"Gon\u00e7alves NP, Vieira P, Saraiva MJ (2014) Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis. Amyloid 21:175\u2013184","journal-title":"Amyloid"},{"key":"3778_CR12","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"HH Schmidt","year":"2018","unstructured":"Schmidt HH, Waddington-Cruz M, Botteman MF, Carter JA, Chopra AS, Hopps M, Stewart M, Fallet S, Amass L (2018) Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve 57:829\u2013837","journal-title":"Muscle Nerve"},{"key":"3778_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Plant\u00e9-Bordeneuve V, Rapezzi C, Said G, Salvi F (2013) Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 8:31","journal-title":"Orphanet J Rare Dis"},{"key":"3778_CR14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s00415-017-8708-4","volume":"265","author":"V Plant\u00e9-Bordeneuve","year":"2018","unstructured":"Plant\u00e9-Bordeneuve V (2018) Transthyretin familial amyloid polyneuropathy: an update. J Neurol 265:976\u2013983","journal-title":"J Neurol"},{"key":"3778_CR15","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.21037\/jtd.2018.03.134","volume":"10","author":"IG Halatchev","year":"2018","unstructured":"Halatchev IG, Zheng J, Ou J (2018) Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies. J Thorac Dis 10:2034\u20132045","journal-title":"J Thorac Dis"},{"key":"3778_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mus.20821","volume":"36","author":"MD Benson","year":"2007","unstructured":"Benson MD, Kincaid JC (2007) The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36:411\u2013423","journal-title":"Muscle Nerve"},{"key":"3778_CR17","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.3233\/JND-150091","volume":"2","author":"A Mazzeo","year":"2015","unstructured":"Mazzeo A, Russo M, Di Bella G, Minutoli F, Stancanelli C, Gentile L, Baldari S, Carerj S, Toscano A, Vita G (2015) Transthyretin-related familial amyloid polyneuropathy (TTR-FAP): a single-center experience in Sicily, an Italian endemic area. J Neuromuscul Dis 2:S39\u2013S48","journal-title":"J Neuromuscul Dis"},{"key":"3778_CR18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/jnnp-2015-310907","volume":"87","author":"AS Carr","year":"2016","unstructured":"Carr AS, Pelayo-Negro AL, Evans MR, Laur\u00e0 M, Blake J, Stancanelli C, Iodice V, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Reilly MM (2016) A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. J Neurol Neurosurg Psychiatry 87:620\u2013627","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3778_CR19","doi-asserted-by":"publisher","unstructured":"Gonzalez-Duarte A (2018) Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis). Clin Auton Res. \n                    https:\/\/doi.org\/10.1007\/s10286-018-0514-2","DOI":"10.1007\/s10286-018-0514-2"},{"key":"3778_CR20","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/ehjci\/jeu158","volume":"15","author":"G Bella Di","year":"2014","unstructured":"Di Bella G, Pizzino F, Minutoli F, Zito C, Donato R, Dattilo G, Oreto G, Baldari S, Vita G, Khandheria BK, Carerj S (2014) The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease. Eur Heart J Cardiovasc Imaging 15:1307\u20131315","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"3778_CR21","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1253\/circj.CJ-16-0209","volume":"80","author":"G Bella Di","year":"2016","unstructured":"Di Bella G, Minutoli F, Piaggi P, Casale M, Mazzeo A, Zito C, Oreto G, Baldari S, Vita G, Pingitore A, Khandheria BK, Carerj S (2016) Quantitative comparison between amyloid deposition detected by (99m)Tc-diphosphonate imaging and myocardial deformation evaluated by strain echocardiography in transthyretin-related cardiac amyloidosis. Circ J 80:1998\u20132003","journal-title":"Circ J"},{"key":"3778_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","volume":"88","author":"A Cortese","year":"2017","unstructured":"Cortese A, Vegezzi E, Lozza A, Alfonsi E, Montini A, Moglia A, Merlini G, Obici L (2017) Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry 88:457\u2013458","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3778_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Concei\u00e7\u00e3o","year":"2016","unstructured":"Concei\u00e7\u00e3o I, Gonz\u00e1lez-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L (2016) \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 21:5\u20139","journal-title":"J Peripher Nerv Syst"},{"key":"3778_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","volume":"13","author":"Y Sekijima","year":"2018","unstructured":"Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y (2018) Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis 13:6","journal-title":"Orphanet J Rare Dis"},{"key":"3778_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","volume":"85","author":"D Adams","year":"2015","unstructured":"Adams D, Coelho T, Obici L, Merlini G, Mincheva Z, Suanprasert N, Bettencourt BR, Gollob JA, Gandhi PJ, Litchy WJ, Dyck PJ (2015) Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology 85:675\u2013682","journal-title":"Neurology"},{"issue":"Suppl 1","key":"3778_CR26","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","volume":"29","author":"D Adams","year":"2016","unstructured":"Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, Slama MS, Hazenberg BP, Coelho T, European Network for TTR-FAP (ATTReuNET) (2016) First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 29(Suppl 1):S14\u2013S26","journal-title":"Curr Opin Neurol"},{"key":"3778_CR27","doi-asserted-by":"publisher","unstructured":"Vita GL, Stancanelli C, Gentile L, Barcellona C, Russo M, Di Bella G, Vita G, Mazzeo A (2018) 6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR). Neuromuscul Disord. \n                    https:\/\/doi.org\/10.1016\/j.nmd.2018.11.002","DOI":"10.1016\/j.nmd.2018.11.002"},{"key":"3778_CR28","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","volume":"99","author":"BG Ericzon","year":"2015","unstructured":"Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, Barroso E, Daniel J, Samuel D, Adam R, Karam V, Poterucha J, Lewis D, Ferraz-Neto BH, Cruz MW, Munar-Ques M, Fabregat J, Ikeda S, Ando Y, Heaton N, Otto G, Suhr O (2015) Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99:1847\u20131854","journal-title":"Transplantation"},{"key":"3778_CR29","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/tri.13326","volume":"31","author":"J Vollmar","year":"2018","unstructured":"Vollmar J, Schmid JC, Hoppe-Lotichius M, Barreiros AP, Azizi M, Emrich T, Geber C, Schad A, Weyer V, Otto G, Heise M, Mittler J, Birklein F, Lang H, Galle PR, Zimmermann T (2018) Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study. Transpl Int 31:1207\u20131215","journal-title":"Transpl Int"},{"key":"3778_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.nmd.2016.03.006","volume":"26","author":"M Russo","year":"2016","unstructured":"Russo M, Vita GL, Stancanelli C, Mazzeo A, Vita G, Messina S (2016) Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy. Neuromuscul Disord 26:374\u2013377","journal-title":"Neuromuscul Disord"},{"key":"3778_CR31","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plant\u00e9-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Concei\u00e7\u00e3o IM, Schmidt HH, Trigo P, Kelly JW, Labaudini\u00e8re R, Chan J, Packman J, Wilson A, Grogan DR (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79:785\u2013792","journal-title":"Neurology"},{"key":"3778_CR32","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","volume":"260","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maia LF, da Silva AM, Cruz MW, Plant\u00e9-Bordeneuve V, Suhr OB, Concei\u00e7ao I, Schmidt HH, Trigo P, Kelly JW, Labaudini\u00e8re R, Chan J, Packman J, Grogan DR (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260:2802\u20132814","journal-title":"J Neurol"},{"key":"3778_CR33","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/ene.12225","volume":"20","author":"P Lozeron","year":"2013","unstructured":"Lozeron P, Th\u00e9audin M, Mincheva Z, Ducot B, Lacroix C, Adams D, French Network for FAP (CORNAMYL) (2013) Effect on disability and safety of tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol 20:1539\u20131545","journal-title":"Eur J Neurol"},{"key":"3778_CR34","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","volume":"6","author":"G Merlini","year":"2013","unstructured":"Merlini G, Plant\u00e9-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, Packman J, Tripp T, Grogan DR (2013) Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 6:1011\u20131020","journal-title":"J Cardiovasc Transl Res"},{"key":"3778_CR35","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","volume":"263","author":"A Cortese","year":"2016","unstructured":"Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D (2016) Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol 263:916\u2013924","journal-title":"J Neurol"},{"key":"3778_CR36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","volume":"23","author":"M Waddington Cruz","year":"2016","unstructured":"Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B (2016) Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid 23:178\u2013183","journal-title":"Amyloid"},{"key":"3778_CR37","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","volume":"264","author":"V Plant\u00e9-Bordeneuve","year":"2017","unstructured":"Plant\u00e9-Bordeneuve V, Gorram F, Salhi H, Nordine T, Ayache SS, Le Corvoisier P, Azoulay D, Feray C, Damy T, Lefaucheur JP (2017) Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol 264:268\u2013276","journal-title":"J Neurol"},{"key":"3778_CR38","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007\u20131016","journal-title":"N Engl J Med"},{"key":"3778_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plant\u00e9-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11\u201321","journal-title":"N Engl J Med"},{"key":"3778_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plant\u00e9-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Concei\u00e7\u00e3o I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, BW ME, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22\u201331","journal-title":"N Engl J Med"},{"key":"3778_CR41","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","volume":"23","author":"EJ Ackermann","year":"2016","unstructured":"Ackermann EJ, Guo S, Benson MD, Booten S, Freier S, Hughes SG, Kim TW, Jesse Kwoh T, Matson J, Norris D, Yu R, Watt A, Monia BP (2016) Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides. Amyloid 23:148\u2013157","journal-title":"Amyloid"},{"key":"3778_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","volume":"10","author":"OB Suhr","year":"2015","unstructured":"Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, Schmidt H, Waddington-Cruz M, Campistol JM, Bettencourt BR, Vaishnaw A, Gollob J, Adams D (2015) Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 10:109","journal-title":"Orphanet J Rare Dis"},{"key":"3778_CR43","doi-asserted-by":"crossref","unstructured":"Plant\u00e9-Bordeneuve V, Lin H, Gollob J, Agarwal S, Betts M, Fahrbach K, Chitnis M, Polydefkis M (2019) An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opin Pharmacother 20:473\u2013481","DOI":"10.1080\/14656566.2018.1554648"},{"key":"3778_CR44","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/B978-0-444-64076-5.00042-9","volume":"148","author":"C Pisciotta","year":"2018","unstructured":"Pisciotta C, Shy ME (2018) Neuropathy. Handb Clin Neurol 148:653\u2013665","journal-title":"Handb Clin Neurol"},{"key":"3778_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1385\/NMM:8:1-2:3","volume":"8","author":"D Pareyson","year":"2006","unstructured":"Pareyson D, Scaioli V, Laur\u00e0 M (2006) Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease. NeuroMolecular Med 8:3\u201322","journal-title":"NeuroMolecular Med"},{"key":"3778_CR46","first-page":"1993","volume-title":"GeneReviews\u00ae [Internet]","author":"TD Bird","year":"1998","unstructured":"Bird TD (1998) Charcot-Marie-Tooth (CMT) hereditary neuropathy overview. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (eds) GeneReviews\u00ae [Internet]. University of Washington, Seattle, pp 1993\u20132018"},{"key":"3778_CR47","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/jns.12116","volume":"20","author":"AD Sman","year":"2015","unstructured":"Sman AD, Hackett D, Fiatarone Singh M, Fornusek C, Menezes MP, Burns J (2015) Systematic review of exercise for Charcot-Marie-Tooth disease. J Peripher Nerv Syst 20:347\u2013362","journal-title":"J Peripher Nerv Syst"},{"key":"3778_CR48","doi-asserted-by":"publisher","first-page":"e3278","DOI":"10.1097\/MD.0000000000003278","volume":"95","author":"B Corrado","year":"2016","unstructured":"Corrado B, Ciardi G, Bargigli C (2016) Rehabilitation management of the Charcot-Marie-Tooth syndrome: a systematic review of the literature. Medicine (Baltimore) 95:e3278","journal-title":"Medicine (Baltimore)"},{"key":"3778_CR49","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.nmd.2016.06.002","volume":"26","author":"G Vita","year":"2016","unstructured":"Vita G, La Foresta S, Russo M, Vita GL, Messina S, Lunetta C, Mazzeo A (2016) Sport activity in Charcot-Marie-Tooth disease: a case study of a Paralympic swimmer. Neuromuscul Disord 26:614\u2013618","journal-title":"Neuromuscul Disord"},{"key":"3778_CR50","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1136\/jnnp-2014-307598","volume":"85","author":"G Piscosquito","year":"2014","unstructured":"Piscosquito G, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Vita G, Quattrone A, Padua L, Gemignani F, Visioli F, Laur\u00e0 M, Calabrese D, Hughes RA, Radice D, Solari A, Pareyson D, CMT-TRIAAL & CMT-TRAUK Group (2014) Is overwork weakness relevant in Charcot-Marie-Tooth disease? J Neurol Neurosurg Psychiatry 85:1354\u20131358","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3778_CR51","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/WCO.0000000000000474","volume":"30","author":"D Pareyson","year":"2017","unstructured":"Pareyson D, Saveri P, Pisciotta C (2017) New developments in Charcot-Marie-Tooth neuropathy and related diseases. Curr Opin Neurol 30:471\u2013480","journal-title":"Curr Opin Neurol"},{"key":"3778_CR52","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/ene.13033","volume":"23","author":"L Padua","year":"2016","unstructured":"Padua L, Pazzaglia C, Pareyson D, Schenone A, Aiello A, Fabrizi GM, Cavallaro T, Santoro L, Manganelli F, Gemignani F, Vitetta F, Quattrone A, Mazzeo A, Russo M, Vita G, CMT-TRIAAL Group (2016) Novel outcome measures for Charcot-Marie-Tooth disease: validation and reliability of the 6-min walk test and StepWatch(\u2122) Activity Monitor and identification of the walking features related to higher quality of life. Eur J Neurol 23:1343\u20131350","journal-title":"Eur J Neurol"},{"key":"3778_CR53","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1093\/brain\/awy280","volume":"141","author":"MR Mandarakas","year":"2018","unstructured":"Mandarakas MR, Menezes MP, Rose KJ, Shy R, Eichinger K, Foscan M, Estilow T, Kennedy R, Herbert K, Bray P, Refshauge K, Ryan MM, Yiu EM, Farrar M, Sampaio H, Moroni I, Pagliano E, Pareyson D, Yum SW, Herrmann DN, Acsadi G, Shy ME, Burns J, Sanmaneechai O (2018) Development and validation of the Charcot-Marie-Tooth Disease Infant Scale. Brain 141:3319\u20133330","journal-title":"Brain"},{"key":"3778_CR54","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/jnnp-2018-318834","volume":"90","author":"M Juneja","year":"2019","unstructured":"Juneja M, Burns J, Saporta MA, Timmerman V (2019) Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development. J Neurol Neurosurg Psychiatry 90:58\u201367","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3778_CR55","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1172\/JCI96499","volume":"128","author":"HT Zhao","year":"2018","unstructured":"Zhao HT, Damle S, Ikeda-Lee K, Kuntz S, Li J, Mohan A, Kim A, Hung G, Scheideler MA, Scherer SS, Svaren J, Swayze EE, Kordasiewicz HB (2018) PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. J Clin Invest 128:359\u2013368","journal-title":"J Clin Invest"},{"key":"3778_CR56","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fncel.2012.00068","volume":"6","author":"P Procacci","year":"2013","unstructured":"Procacci P, Ballabio M, Castelnovo LF, Mantovani C, Magnaghi V (2013) GABA-B receptors in the PNS have a role in Schwann cells differentiation? Front Cell Neurosci 6:68","journal-title":"Front Cell Neurosci"},{"key":"3778_CR57","doi-asserted-by":"publisher","first-page":"e1554","DOI":"10.1371\/journal.pone.0001554","volume":"3","author":"HY Wang","year":"2008","unstructured":"Wang HY, Frankfurt M, Burns LH (2008) High-affinity naloxone binding to filamin a prevents mu opioid receptor-Gs coupling underlying opioid tolerance and dependence. PLoS One 3:e1554","journal-title":"PLoS One"},{"key":"3778_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.abb.2009.09.007","volume":"491","author":"R Kumar","year":"2009","unstructured":"Kumar R (2009) Role of naturally occurring osmolytes in protein folding and stability (2009). Arch Biochem Biophys 491:1\u20136","journal-title":"Arch Biochem Biophys"},{"key":"3778_CR59","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1021\/bi301635f","volume":"52","author":"JP Schlebach","year":"2013","unstructured":"Schlebach JP, Peng D, Kroncke BM, Mittendorf KF, Narayan M, Carter BD, Sanders CR (2013) Reversible folding of human peripheral myelin protein 22, a tetraspan membrane protein. Biochemistry 52:3229\u20133241","journal-title":"Biochemistry"},{"key":"3778_CR60","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13023-014-0201-x","volume":"9","author":"I Chumakov","year":"2014","unstructured":"Chumakov I, Milet A, Cholet N, Primas G, Boucard A, Pereira Y, Graudens E, Mandel J, Laffaire J, Foucquier J, Glibert F, Bertrand V, Nave KA, Sereda MW, Vial E, Guedj M, Hajj R, Nabirotchkin S, Cohen D (2014) Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet J Rare Dis 9:201","journal-title":"Orphanet J Rare Dis"},{"key":"3778_CR61","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13023-014-0199-0","volume":"9","author":"S Attarian","year":"2014","unstructured":"Attarian S, Vallat JM, Magy L, Funalot B, Gonnaud PM, Lacour A, P\u00e9r\u00e9on Y, Dubourg O, Pouget J, Micallef J, Franques J, Lefebvre MN, Ghorab K, Al-Moussawi M, Tiffreau V, Preudhomme M, Magot A, Leclair-Visonneau L, Stojkovic T, Bossi L, Lehert P, Gilbert W, Bertrand V, Mandel J, Milet A, Hajj R, Boudiaf L, Scart-Gr\u00e8s C, Nabirotchkin S, Guedj M, Chumakov I, Cohen D (2014) An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J Rare Dis 9:199","journal-title":"Orphanet J Rare Dis"},{"key":"3778_CR62","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13023-016-0463-6","volume":"11","author":"S Attarian","year":"2016","unstructured":"Attarian S, Vallat JM, Magy L, Funalot B, Gonnaud PM, Lacour A, P\u00e9r\u00e9on Y, Dubourg O, Pouget J, Micallef J, Franques J, Lefebvre MN, Ghorab K, Al-Moussawi M, Tiffreau V, Preudhomme M, Magot A, Leclair-Visonneau L, Stojkovic T, Bossi L, Lehert P, Gilbert W, Bertrand V, Mandel J, Milet A, Hajj R, Boudiaf L, Scart-Gr\u00e8s C, Nabirotchkin S, Guedj M, Chumakov I, Cohen D (2016) Erratum to: an exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-tooth disease type 1A. Orphanet J Rare Dis 11:92","journal-title":"Orphanet J Rare Dis"},{"key":"3778_CR63","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.amjmed.2014.10.026","volume":"128","author":"DM Bissell","year":"2015","unstructured":"Bissell DM, Lai JC, Meister RK, Blanc PD (2015) Role of delta-aminolevulinic acid in the symptoms of acute porphyria. Am J Med 128:313\u2013317","journal-title":"Am J Med"},{"key":"3778_CR64","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/bjh.14459","volume":"176","author":"PE Stein","year":"2017","unstructured":"Stein PE, Badminton MN, Rees DC (2017) Update review of the acute porphyrias. Br J Haematol 176:527\u2013538","journal-title":"Br J Haematol"},{"key":"3778_CR65","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/humu.23067","volume":"37","author":"B Chen","year":"2016","unstructured":"Chen B, Solis-Villa C, Hakenberg J, Qiao W, Srinivasan RR, Yasuda M, Balwani M, Doheny D, Peter I, Chen R, Desnick RJ (2016) Acute intermittent porphyria: predicted pathogenicity of HMBS variants indicates extremely low penetrance of the autosomal dominant disease. Hum Mutat 37:1215\u20131222","journal-title":"Hum Mutat"},{"key":"3778_CR66","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/B978-0-7020-4087-0.00056-5","volume":"120","author":"JA Tracy","year":"2014","unstructured":"Tracy JA, Dyck PJ (2014) Porphyria and its neurologic manifestations. Handb Clin Neurol 120:839\u2013849","journal-title":"Handb Clin Neurol"},{"key":"3778_CR67","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40271-018-0319-3","volume":"11","author":"A Simon","year":"2018","unstructured":"Simon A, Pompilus F, Querbes W, Wei A, Strzok S, Penz C, Howe DL, Hungate JR, Kim JB, Agarwal S, Marquis P (2018) Patient perspective on acute intermittent porphyria with frequent attacks: a disease with intermittent and chronic manifestations. Patient 11:527\u2013537","journal-title":"Patient"},{"key":"3778_CR68","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/jclinpath-2012-201367","volume":"67","author":"JT Marsden","year":"2014","unstructured":"Marsden JT, Rees DC (2014) Urinary excretion of porphyrins, porphobilinogen and \u03b4-aminolaevulinic acid following an attack of acute intermittent porphyria. J Clin Pathol 67:60\u201365","journal-title":"J Clin Pathol"},{"key":"3778_CR69","doi-asserted-by":"publisher","first-page":"801.e19","DOI":"10.1016\/j.amjmed.2006.05.026","volume":"119","author":"KE Anderson","year":"2006","unstructured":"Anderson KE, Collins S (2006) Open-label study of hemin for acute porphyria: clinical practice implications. Am J Med 119:801.e19\u2013801.e24","journal-title":"Am J Med"},{"key":"3778_CR70","doi-asserted-by":"publisher","first-page":"7777","DOI":"10.1073\/pnas.1406228111","volume":"111","author":"M Yasuda","year":"2014","unstructured":"Yasuda M, Gan L, Chen B, Kadirvel S, Yu C, Phillips JD, New MI, Liebow A, Fitzgerald K, Querbes W, Desnick RJ (2014) RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. Proc Natl Acad Sci U S A 111:7777\u20137782","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3778_CR71","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1038\/mtna.2015.36","volume":"4","author":"A Chan","year":"2015","unstructured":"Chan A, Liebow A, Yasuda M, Gan L, Racie T, Maier M, Kuchimanchi S, Foster D, Milstein S, Charisse K, Sehgal A, Manoharan M, Meyers R, Fitzgerald K, Simon A, Desnick RJ, Querbes W (2015) Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification. Mol Ther Nucleic Acids 4:e263","journal-title":"Mol Ther Nucleic Acids"},{"key":"3778_CR72","doi-asserted-by":"crossref","unstructured":"Filosto M, Cotti Piccinelli S, Caria F, Gallo Cassarino S, Baldelli E, Galvagni A, Volonghi I, Scarpelli M, Padovani A (2018) Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE-MTDPS1). J Clin Med 7(11):E389","DOI":"10.3390\/jcm7110389"},{"key":"3778_CR73","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/brain\/awv226","volume":"138","author":"JP Halter","year":"2015","unstructured":"Halter JP, Michael W, Sch\u00fcpbach M, Mandel H, Casali C, Orchard K, Collin M, Valcarcel D, Rovelli A, Filosto M, Dotti MT, Marotta G, Pintos G, Barba P, Accarino A, Ferra C, Illa I, Beguin Y, Bakker JA, Boelens JJ, de Coo IF, Fay K, Sue CM, Nachbaur D, Zoller H, Sobreira C, Pinto Simoes B, Hammans SR, Savage D, Mart\u00ed R, Chinnery PF, Elhasid R, Gratwohl A, Hirano M (2015) Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain 138:2847\u20132858","journal-title":"Brain"},{"key":"3778_CR74","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mito.2017.02.006","volume":"34","author":"R D\u2019Angelo","year":"2017","unstructured":"D\u2019Angelo R, Rinaldi R, Pironi L, Dotti MT, Pinna AD, Boschetti E, Capristo M, Mohamed S, Contin M, Caporali L, Carelli V, De Giorgio R (2017) Liver transplant reverses biochemical imbalance in mitochondrial neurogastrointestinal encephalomyopathy. Mitochondrion 34:101\u2013102","journal-title":"Mitochondrion"},{"key":"3778_CR75","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1089\/hum.2017.133","volume":"29","author":"J Torres-Torronteras","year":"2018","unstructured":"Torres-Torronteras J, Cabrera-P\u00e9rez R, Vila-Juli\u00e0 F, Viscomi C, C\u00e1mara Y, Hirano M, Zeviani M, Mart\u00ed R (2018) Long-term sustained effect of liver-targeted adeno-associated virus gene therapy for mitochondrial neurogastrointestinal encephalomyopathy. Hum Gene Ther 29:708\u2013718","journal-title":"Hum Gene Ther"},{"key":"3778_CR76","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/mus.25210","volume":"54","author":"HH Schmidt","year":"2016","unstructured":"Schmidt HH, Barroso F, Gonz\u00e1lez-Duarte A, Concei\u00e7\u00e3o I, Obici L, Keohane D, Amass L (2016) Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. Muscle Nerve 54:353\u2013360","journal-title":"Muscle Nerve"},{"key":"3778_CR77","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13023-018-0918-z","volume":"13","author":"A Ambrosini","year":"2018","unstructured":"Ambrosini A, Calabrese D, Avato FM, Catania F, Cavaletti G, Pera MC, Toscano A, Vita G, Monaco L, Pareyson D (2018) The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage. Orphanet J Rare Dis 13:176","journal-title":"Orphanet J Rare Dis"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-019-03778-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-019-03778-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-019-03778-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T19:06:44Z","timestamp":1582916804000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-019-03778-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["3778"],"URL":"https:\/\/doi.org\/10.1007\/s10072-019-03778-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]},"assertion":[{"value":"2 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G.V. discloses having been on advisory board for Alnylam Therap., Akcea Therap, and Pfizer. He is also principal investigator in clinical trials sponsored by Alnylam Therap and Ionis Therap.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}